SCHEMBL24309240

SCHEMBL24309240

Cc1cccc(C)c1-c1cc(Oc2cnc(N3CCN(C)CC3)c(F)c2)nc(NS(=O)(=O)c2cnn(C)c2)n1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 1/20 0.36
▸ TP53 P04637 1/20 0.36
▸ GAA P10253 1/20 0.36
▸ HPGD P15428 1/20 0.36
▸ MAP4K1 Q92918 7/20 0.36
▸ BRD4 O60885 8/20 0.36
▸ DGAT2 Q96PD7 1/20 0.35
▸ JAK1 P23458 1/20 0.34
▸ JAK3 P52333 1/20 0.34
▸ BRDT Q58F21 1/20 0.34
▸ CCNT1 O60563 1/20 0.34
▸ CCNB2 O95067 1/20 0.34
▸ CCNE2 O96020 1/20 0.34
▸ CDK1 P06493 1/20 0.34
▸ CCNB1 P14635 1/20 0.34
▸ CCNE1 P24864 1/20 0.34
▸ CDK2 P24941 1/20 0.34
▸ CDK9 P50750 1/20 0.34
▸ CDK5 Q00535 1/20 0.34
▸ CDK5R1 Q15078 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29566640 1.00 ALDH1A1 (0.36) ALDH1A1TP53GAAHPGDMAP4K1
SCHEMBL29566772 0.88 DGAT2 (0.38) ALDH1A1TP53GAAHPGDMAP4K1
SCHEMBL26806460 0.88 DGAT2 (0.38) ALDH1A1TP53GAAHPGDMAP4K1
SCHEMBL29567227 0.86 MAP4K1 (0.43) MAP4K1BRD4DGAT2JAK1JAK3
SCHEMBL24310343 0.86 MAP4K1 (0.43) MAP4K1BRD4DGAT2JAK1JAK3
SCHEMBL24310014 0.86 HTR1A (0.42) MAP4K1BRD4JAK3METJAK2
SCHEMBL24309675 0.86 MAP4K1 (0.37) ALDH1A1TP53GAAHPGDMAP4K1
SCHEMBL29566817 0.85 EGFR (0.37) ALDH1A1TP53GAAHPGDMAP4K1
SCHEMBL24309686 0.85 EGFR (0.37) ALDH1A1TP53GAAHPGDMAP4K1
SCHEMBL26808353 0.85 HTR1A (0.39) ALDH1A1TP53GAAHPGDBRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed
WO-2022076627-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2022-04-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, SCNN1G, SCNN1B ALDH1A1 3992/4885TP53 3197/4885GAA 904/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback